Compare · BDX vs TCMD
BDX vs TCMD
Side-by-side comparison of Becton Dickinson and Company (BDX) and Tactile Systems Technology Inc. (TCMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and TCMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $42.57B, about 66.5x TCMD ($640.4M).
- Over the past year, BDX is down 12.0% and TCMD is up 194.5% - TCMD leads by 206.4 points.
- BDX has been more active in the news (4 items in the past 4 weeks vs 2 for TCMD).
- BDX has more recent analyst coverage (25 ratings vs 9 for TCMD).
- Company
- Becton Dickinson and Company
- Tactile Systems Technology Inc.
- Price
- $154.43-2.36%
- $28.43-0.80%
- Market cap
- $42.57B
- $640.4M
- 1M return
- +9.01%
- +10.02%
- 1Y return
- -11.95%
- +194.46%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 9
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Tactile Systems Technology Inc.
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; and Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest TCMD
- Tactile Systems Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients
- Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
- Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
- CHIEF FINANCIAL OFFICER Birkemeyer Elaine M. sold $113,404 worth of shares (4,631 units at $24.49), decreasing direct ownership by 3% to 130,188 units (SEC Form 4)
- SEC Form 144 filed by Tactile Systems Technology Inc.
- Director Asbury Valerie L. was granted 6,521 shares, increasing direct ownership by 13% to 55,343 units (SEC Form 4)
- Director Huggenberger Raymond was granted 6,521 shares, increasing direct ownership by 12% to 62,841 units (SEC Form 4)
- Director King Laura G. was granted 6,521 shares, increasing direct ownership by 34% to 25,569 units (SEC Form 4)
- Director Pearson Andrea was granted 6,521 shares, increasing direct ownership by 765% to 7,373 units (SEC Form 4)